Crossmark

Evaluating artesunate monotherapy and dihydroartemisinin-piperaquine as potential antimalarial options for prevaccination radical cures during future malaria vaccine field efficacy trials

Crossref DOI link: https://doi.org/10.1186/s12936-024-05198-1

Published Online: 2024-12-18

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Ouédraogo, Alphonse

Ouattara, Daouda

Ouattara, San Maurice

Diarra, Amidou

Badoum, Emilie S.

Hema, Alimatou

Ouédraogo, Amidou Z.

Hien, Denise

Bougouma, Edith C.

Nébié, Issa

Bocquet, Valéry

Vaillant, Michel

Tiono, Alfred B.

Sirima, Sodiomon B.
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct04601714 at ClinicalTrials.gov

Documents that mention this clinical trial

Evaluating artesunate monotherapy and dihydroartemisinin-piperaquine as potential antimalarial options for prevaccination radical cures during future malaria vaccine field efficacy trials
https://doi.org/10.1186/s12936-024-05198-1
License Information

Text and Data Mining valid from 2024-12-18

Version of Record valid from 2024-12-18
More Information

Article History

Received: 27 August 2024

Accepted: 26 November 2024

First Online: 18 December 2024

Declarations

:

: The study was approved by the National Ethics Committee of the Ministry of Health (under deliberation No. 2020-6-101 dated 10/06/2020).

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below